To: Cagen, Stuart Z SCC <stuart.cagen@shell.com> From: Owen, David DE SC-CHSE-DO </O=SHELUOU=OPC/CN=RECIPIENTS/CN=SNDOW4> Cc: Bcc: Received Date: 2003-04-0420:45:17 GMT Subject: Out of Office AutoReply: Benzene Shanghai I am in Brussels on 27 and 28th March.

To: From: Cc: Bcc: Received Date: Subject: Owen, David DE SC-CHSE-DO <david.owen@shell.com> Cagen, Stuart Z SCC-HSE <lO=SHELLlOU=MSXSCC/CN=RECI PI ENTS/CN=SC724012> 2004-03-2614:35:28 GMT RE: CF Issues I spoke with Mike about this on Wednesday and have drafted a BO and Benzene Shanghai document See attached.

To: 'a.r.schnatter@exxonmobil.com' <a.r.schnatter@exxonmobil.com>; Elizabeth_Moran@americanchemistry.com <E lizabeth_Moran@americanchemistry.com> From: Cagen, Stuart Z SHLOIL-SHOIL-SHS </O=SHE LUOU=MSXSCC/CN=RE CI PI ENTS/CN=SC724012> Cc: david. dutton@ innovene. com <david. dutton@ innovene. com>; leej i@cpchem.com <Ieeji@cpchem.com>; Ipottenger@dow.com <Ipottenger@dow.com>; Marcy.Banton@Lyondell.com <Marcy.Banton@Lyondell.com>; michael.g.bird@exxonmobil.com <michael.g.bird@exxonmobil.com>; mwlej m @aol.com <mwlej m @aol.com>; Ray-Papciak@huntsman.com <Ray-Papciak@huntsman.com>; r.jeffrey.lewis@exxonmobil.com <r.jeffrey.lewis@exxonmobil.com>; Shelby-Jones@americanchemistry.com <Shelby-Jones@americanchemistry.com>; william.rawson@lw.com <william.rawson@lw.com> Bcc: Received Date: 2006-02-01 22:55:04 GMT Subject: RE: Current Peer Review List Rob and all: Good idea.

To: From: Cc: Bcc: Received Date: Subject: Clegg, Patsy M SCC-CHSE-PC <lO=SHELLlOU=MSXSCC/CN=RECIPIENTS/CN=PH197432> 2003-07-01 23:27:57 GMT RE: Shanghai Health Study - Ethics and Shell Resources Papers - Draft Patsy: Ethics document looks good, particularly with the consortium ethics page.

To: From: Cc: Bcc: Received Date: Subject: Cagen, Stuart Z SCC <stuart.cagen@shell.com>; Clegg, Patsy M SCC-CHSE-PC <patsy.clegg@shell.com>; Tholstrup, Susan C SCC <susan.tholstrup@shell.com>; lannarone, Lauren B SCC-CSEA <Lauren.lannarone@shell.com>; Owen, David DE SC-CHSE-DO <david.owen@shell.com> Tsai, Shan SP SHLOIL-SHLOIL-HE <lO=SHELLlOU=MSXSOC/CN=RECI PI ENTS/CN=ST196949> 2003-04-1415:04:08 GMT RE: Benzene Shanghai Stuart, I made some minor changes.

To: From: Cc: Bcc: Received Date: Subject: 'Paula Podhasky' <Podhaskyp@api.org>; Samuel, Tarita B SCC darita.samuel@shell.com> Cagen, Stuart Z SCC <lO=SHELLlOU=MSXSCC/CN=RECI PI ENTS/CN=SC724012> 2003-05-0619:12:44 GMT Benzene cost tracking Paula: Tarita Samuel (of Shell Chemical LP) has agreed to look through some of the Shanghai Benzene financials to help the consortium get an improved sense of study costs and projections.

To: From: Cc: Bcc: Received Date: Subject: Cagen, Stuart Z SHLOIL-SHOIL-SHS <stuart.cagen@shell.com> Keulemans, Rob LW SI-SHS </O=SHELUOU=SI/CN=RECIPIENTS/CN=NLRKEO> 2006-11-23 16:34:37 GMT RE: Missing Document Control Report(s) better not do it let us see what happens. rob -----Original Message----From: Cagen, Stuart Z SHLOIL-SHOIL-SHS Sent: 23 November 2006 17:25 To: Keulemans, Rob LW SI-SHS Subject: RE: Missing Document Control Report(s) Rob: I have tried to deal with this notice more than once.

To: 'Bruce Jarnot' <jarnotb@api.org> From: Cagen, Stuart Z SHLOIL-SHOIL-SHS </O=SHE LUOU=MSXSCC/CN=RE CI PI ENTS/CN=SC724012> Cc: Bcc: Received Date: 2006-07-1913:55:08 GMT Subject: RE: Shanghai Health Study...

To: From: Cc: Bcc: Received Date: Subject: Snyder, Phil J SCC-DCS/2 <phil.snyder@shell.com> brian.e.doll@exxonmobil.com <brian.e.doll@exxonmobil.com> 2007-03-05 18:03:09 GMT Fw: Shanghai Health Study - Letters withdrawing commitment ----- Forwarded by Brian E DoIl/FairfaX/Mobil-Notes on 03105/07 12:58 PM "Russell White" <whiter@api.or To g> <BenzConsort-OC@listserve.api.org>, <BenzConsort-TC@listserve.api.org>, "BHRC Communications Committee" 03/05/07 12: 11 <benzconsort-cc@ listserve. api. org> PM ~ Subject Shanghai Health Study - Letters withdrawing commitment All, Attached are recent letters from Patsy and Jennifer to Dr.

2004 Meetings and Conference Call Schedule: June 23 (2:00 p.m.

Shanghai Health Study Benzene Health Research Consortium Contract Review Contract Name: 2002-1000098 [APCD] Effective Date: May 2002 Amended May 2003 Renewal Date: February 2004 Terms - payment schedule: Fee for service based on agreed fee schedule not to exceed $420,500 plus expenses up to $40k.

Shanghai Health Study 2001 Actuals Invoiced $2,981,950 Funds Received $2,167,232 Contract Funds Committed ($2,355,573) 200 1 Admin costs ($ 63,737) Balance ($ 252,078) SH ELL-MCCLU RG-065923 Budget Comparison Original Budget 1/01 Case Control DP & ME Studies Science Review Panel Public Affairs API Admin Costs TOTAL COST $19,261,000* * $500K "repayment" to API included in original estimate already deducted Proposed Budget 12/01 Case Control DP & ME Studies Public Affairs API Admin Costs Science Review Panel Ethics Review Panel Path and Cyto genetic workgroups Outside Counsel QAIQC TOTAL COST $22,789,299 SH ELL-MCCLU RG-065924 AUGUST 2003 INVOICE 1 Shanghai Health Research 2 A I B I C I D IE F G August-01 I YEAR 1 H January-02 I 3 Company Name 4 5 BP 6 7 Chevron 8 9 Conoco 10 11 ExxonMobil 12 13 Shell 14 15 16 Column Total 17 18 Cumulative Total 19 20 21 22 2001 Program Cost 23 24 25 15% of total cost 26 27 28 29 30 31 32 Formula 33 (program costlll) (#sharel company) (%) 34 35 36 1 Year 1 invoices billed as percent of 2001 estimated total program cost Commitment NOT TO EXCEED 4,224,000 3,000,000 1,408,000 5,000,000 3,000,000 16,632,000 Share 3 2 1 3 2 11 15% 806,441 537,627 268,814 806,441 537,627 2,956,950 2,956,950 15% 806,441 537,627 268,814 806,441 537,627 2,956,950 5,913,900 19,713,000 1 2,956,950 2002 Program Cost 25% of total cost 2002 Program Cost 25% of total cost Example: Example: ($19,713,000/11) (1 share) (.25) = ($16,632,000/11) (1 share) (.25) = August 28, 2002 SH ELL-MCCLU RG-065925 AUGUST 2003 INVOICE 1 2 3 4 5 6 7 8 9 10 11 12 13 ~ 15 16 17 18 19 20 21 r-2n2 24 25 26 r-2-7- 28 29 30 31 32 33 34 35 36 JI YEAR 2 August-02 K 25% at $19,713,000 1,344,069 896,046 448,023 1,344,069 896,046 L M IN YEAR 3 August-03 "Not to Exceed" Balance remaining 1,267,049 1,028,700 422,349 2,043,049 1,028,700 4,928,253 10,842,153 11,703,747 19,713,000 16,632,000 $448,023 $378,000 August 28, 2002 SH ELL-MCCLU RG-065926 AUGUST 2003 INVOICE 1 Shanghai Health Research 2 A B 3 Company Name 4 5 BP 6 7 Chevron 8 9 Conoco 10 11 ExxonMobil 12 13 Shell 14 15 16 Column Total 17 18 Cumulative Total 19 20 21 22 2001 Program Cost 23 24 25 15% of total cost 26 27 28 29 30 31 32 Formula 33 (program costlll) (#sharel company) (%) 34 35 36 1 Year 1 invoices billed as percent of 2001 estimated total program cost 37 2 Contract value of $1 ,500,000 1 share C D EF Commitment by share2 4,500,000 3,000,000 1,500,000 4,500,000 3,000,000 16,500,000 Share 3 2 1 3 2 11 G August-01 YEAR 1 15% 806,441 537,627 268,814 806,441 537,627 2,956,950 2,956,950 H January-02 15% I 806,441 537,627 268,814 806,441 537,627 2,956,950 5,913,900 19,713,000 1 2,956,950 2002 Program Cost 25% of total cost 2002 Program Cost 25% of total cost Example: Example: ($19,713,000/11) (1 share) (.25) = ($16,632,000/11) (1 share) (.25) = August 28, 2002 SH ELL-MCCLU RG-065927 AUGUST 2003 INVOICE 1 2 3 4 5 6 7 8 9 10 11 12 13 14 '15 16 17 18 19 20 21 22 "23 24 25 26 r2-7- 28 29 30 31 32 33 34 35 36 37 J YEAR 2 August-02 K 25% at $19,713,000 1,344,069 896,046 448,023 1,344,069 896,046 4,928,253 10,842,153 LM YEAR 3 August-03 Share Balance remaining 1,543,049 1,028,700 514,349 1,543,049 1,028,700 11,571,747 19,713,000 16,632,000 $448,023 $378,000 August 28, 2002 SH ELL-MCCLU RG-065928 BENZENE HEALTH RESEARCH CONSORTIUM For Discussion - Options for Revised Number of Shares April 21, 2004 Option #1 (Give each of the 4 companies who agreed to provided additional funding above the original commitment an additional share.)

Shanghai Health Study - Conference call Friday, April 13 at 4 PM EDTFrom: Howard Feldman [Feldman@api.org] Sent: Friday, April 13, 2007 8:48 AM To: BenzConsort-OC@listserve.api.org; BenzConsort-TC@listserve.api.org; BHRC Communications Committee; myron.c.harrison@exxonmobil.com; Snyder, Phil J SDIUS-DXX/9; Bob Greco; Brenda Hargett; Harry Ng Subject: RE: Shanghai Health Study - Conference call Friday, April 13 at 4 PM EDT BHRC, In advance of today's call, the draft follow-up List of Actions flowing from Wednesday's API Executive Committee call is listed below.

The Shanghai Health Study Patsy Clegg/Stuart Cagen March 2003 SHELL-MCCLURG-068137 The Shanghai Health Study :~::.::~: Path to developing the study: IJ Pre-97: 97::::H::::: Benzene exposure associated with AML NCI published conclusions from China study that: - Benzene can cause NHL - AML develops at exposures lower than previously known - no threshold observed NCI Methodology criticized Feasibility studies in Shanghai Benzene Health Study Consortium formed to: - do a study to test conclusions - answer questions of disease progression and biomarkers SHELL-MCCLURG-068138 Benzene exposure and cancer Conclusions from pre-1997 Epidemiology :~:~:I:~::~ Only acute myelogenous leukemia (AML) associated with benzene :t!

al/3LfZaat) aZI by iLZ bauyizb U 1X HUUb UN bHH LIB Hwbt vZ/ab Scand J Work Environ Health 2005:3 T supoi2:27-30 Asbestos hazard in the Swedish construction industry--recent trends in by Goran Engholm, MSc,] Anders England, MDS Engholm G, Englund A.